I-Mab Stock Flashes Vital Signs With 89 RS Rating

I-Mab (IMAB) had its Relative Strength Rating upgraded from 70 to 89 on Wednesday. Is I-Mab stock on your radar?


When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.

This exclusive rating from Investor’s Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock’s price behavior over the trailing 52 weeks holds up against all the other stocks in our database.

Over 100 years of market history reveals that the best-performing stocks typically have an 80 or better RS Rating in the early stages of their moves. So the 89 RS Rating for I-Mab stock is noteworthy.

Looking For Winning Stocks? Try This Simple Routine

Is I-Mab Stock In The Buy Zone?

I-Mab stock is trying to complete a consolidation with an 85.50 entry. See if I-Mab stock can break out in heavy trading. It’s a later-stage pattern, and investors should be aware that those involve more risk.

Earnings growth for the clinical-stage biopharma company worsened last quarter from flat to -79%. But sales growth dramatically improved, from -100% to 5,528%.

I-Mab stock earns the No. 65 rank among its peers in the Medical-Biomed/Biotech industry group. Maravai LifeSciences (MRVI) and BioNTech (BNTX) are also among the group’s highest-rated stocks.


Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button